Who are HLX04, a bevacizumab biosimilar's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intralesional injection of bevacizumab.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hlx04-a-bevacizumab-biosimilar.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

HLX04, a bevacizumab biosimilar — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HLX04, a bevacizumab biosimilar (HLX04, a bevacizumab biosimilar) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody (VEGF inhibitor). Area: Oncology.

phase 3 Monoclonal antibody (VEGF inhibitor) VEGF (Vascular Endothelial Growth Factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

HLX04, a bevacizumab biosimilar (HLX04, a bevacizumab biosimilar) — Shanghai Henlius Biotech. HLX04 is a monoclonal antibody that binds to and inhibits vascular endothelial growth factor (VEGF), blocking tumor angiogenesis and reducing blood supply to cancer cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
HLX04, a bevacizumab biosimilar TARGET	HLX04, a bevacizumab biosimilar	Shanghai Henlius Biotech	phase 3	Monoclonal antibody (VEGF inhibitor)	VEGF (Vascular Endothelial Growth Factor)
Intralesional injection of bevacizumab	Intralesional injection of bevacizumab	Khon Kaen University	phase 3	Monoclonal antibody (VEGF inhibitor)	VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody (VEGF inhibitor) class)

Khon Kaen University · 1 drug in this class
Shanghai Henlius Biotech · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). HLX04, a bevacizumab biosimilar — Competitive Intelligence Brief. https://druglandscape.com/ci/hlx04-a-bevacizumab-biosimilar. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab